Is Berberine Nature's Metformin? The Proven Results Say Yes
- 11 hours ago
- 13 min read
Dr. Michael Donaldson is a nutrition researcher and health coach specializing in type 2 diabetes reversal. As founder of End Diabetes Now and Research Director at Hallelujah Diet, he empowers people to transform their health through evidence-based, plant-centered nutrition.
Berberine isn’t just a traditional herbal compound, clinical evidence shows it can match metformin’s blood‑sugar‑lowering effects while also improving lipids and inflammation with a generally gentler side‑effect profile. As research expands beyond glucose control into metabolic health, PCOS and longevity, it’s easy to see why many are calling it “Nature’s Metformin.”
What is berberine, and why is it called “nature’s metformin”?
Berberine is a bright yellow alkaloid extracted from the roots and bark of several plants, including goldenseal, barberry, Oregon grape, and Coptis chinensis, an herb used in traditional Chinese medicine for thousands of years. In the early 2000s, Western researchers began looking at berberine in earnest. Early trials showed it could lower blood glucose as effectively as metformin. That comparison stuck, and the nickname “Nature’s Metformin” followed suit.
The comparison is based on head-to-head clinical trials, not a marketing slogan. The growing body of research has revealed that berberine does more than just regulate blood sugar. It can help the body manage blood glucose, improve fat metabolism, and reduce inflammation simultaneously. These effects are systemic, benefiting the whole body. That’s what makes berberine interesting to me, and possibly to you too, even if you don’t have diabetes.
How berberine works, briefly
Berberine and metformin activate many of the same cellular pathways, especially AMPK, the body’s master energy sensor. When AMPK is activated, cells take up more glucose from the blood, the liver reduces its glucose output, fat metabolism improves, and inflammation is reduced. Berberine also improves the gut microbiome, which positively affects the body’s metabolism of fat and sugar. Most of the mechanisms of action for berberine are similar to those of metformin, but the most important thing isn’t the mechanism. It’s the results that people get when they take it.
Blood sugar control: What the clinical trials show
There have not been many trials directly comparing metformin and berberine. The most well-known one was published in 2008 by Yin and colleagues. In adults with newly diagnosed type 2 diabetes, berberine at 500 mg three times daily matched metformin at the same dose across three months. Hemoglobin A1c fell from 9.5% to 7.5%. Fasting blood glucose dropped from 10.6 to 6.9 mmol/L. Post-meal glucose fell from 19.8 to 11.1 mmol/L. On lipids, berberine outperformed metformin, reducing total cholesterol and triglycerides more substantially. This one trial alone is enough to nickname berberine “Nature’s Metformin.” But there’s more, much more.
One of the largest and most rigorous berberine trials to date is the PREMOTE study, published in 2020 by Zhang, Gu, and colleagues. This multicenter randomized controlled trial included 409 newly diagnosed patients with type 2 diabetes across 20 centers in China. Berberine alone reduced A1c by approximately 1% over 12 weeks, an amount that most people would be pleased with from a drug or supplement. The study also identified a specific gut microbiome mechanism underlying berberine’s blood sugar effects, in addition to what we already knew about activating AMPK.
A 2023 randomized double-blind placebo-controlled pilot trial by Panigrahi and Mohanty tested berberine specifically in people with prediabetes, a population often overlooked in supplement research. After 12 weeks on 500 mg three times daily, fasting plasma glucose fell from 6.75 to 5.33 mmol/L, and A1c dropped from 6.4% to 5.43%, bringing both markers below the prediabetic threshold. Two-hour oral glucose tolerance also improved significantly. No liver or kidney toxicity was detected. These results are great news for people with prediabetes, as it gives them a powerful way to get the beneficial effects of something like metformin, without waiting for a diabetes diagnosis.
Research continues to push berberine forward. A 2025 phase 2 clinical trial by Ji and colleagues tested a novel ionic compound pairing berberine with a bile acid in 113 patients with type 2 diabetes. The trial found that A1c dropped 0.7% more than placebo over 12 weeks, with a 97% completion rate. Phase 3 trials are underway.
Cholesterol, lipids, and inflammation: A broad metabolic footprint
Berberine’s effects on the lipid panel have been among the most consistent findings across the clinical literature. A 2024 meta-analysis by Wang and colleagues pooled 50 randomized controlled trials involving 4,150 participants and found that berberine alone significantly reduced LDL cholesterol, total cholesterol, and triglycerides, with even larger effects when combined with standard glucose-lowering medications. For people who can’t or don’t want to take statins, this is an effective alternative. Berberine can also be taken alongside standard diabetic or cardiovascular therapy.
Other trials have added texture to the lipid picture. Zhao and colleagues at the University of Hong Kong found that berberine reduced total cholesterol in men with hyperlipidemia and, unexpectedly, did not lower testosterone and may have modestly increased it, an advantage over metformin, which is well-known to blunt testosterone. A 2026 trial by Lei and colleagues in 337 individuals with fatty liver disease found that berberine did not reduce visceral fat (an honest null finding), but did significantly reduce LDL, apolipoprotein B, and the inflammatory marker CRP, with an excellent six-month safety profile.
Berberine for PCOS: Body composition, hormones, and cardiovascular risk
Polycystic ovary syndrome (PCOS) affects about one in ten women of reproductive age, causing irregular periods, excess androgens, acne, and fertility problems, all driven in large part by insulin resistance. Metformin is frequently prescribed off-label for PCOS. A 2022 three-arm randomized controlled trial by Panigrahi and colleagues in India enrolled 129 women aged 15 to 40 and compared berberine, metformin, and myoinositol head-to-head over three months, with no changes required to diet or exercise.
All three treatments worked. Body weight fell by approximately 4 kg in both the berberine and metformin groups. But berberine stood out in several areas specific to PCOS. Waist circumference decreased by 4 cm in the berberine group, compared with 2 cm in the other groups. As central fat is a key driver of insulin resistance and cardiovascular risk, this distinction is important. Berberine produced the greatest increase in sex hormone binding globulin, which reduces the amount of free testosterone circulating in the blood, and the largest drop in free androgen index overall. On the lipid side, berberine reduced total cholesterol by 13%, LDL by 17%, and raised HDL by 5%. Myoinositol led on insulin sensitivity, metformin performed better on triglycerides specifically. The honest picture is that all three have complementary strengths, but berberine’s benefit profile was the broadest across body composition, hormonal markers, and lipids. Three women in the metformin group dropped out due to gastrointestinal side effects. None dropped out of the berberine group.
Where berberine goes beyond metformin: Unique clinical applications
Metformin has been prescribed to hundreds of millions of people for decades, and doctors know what it works well for. What makes berberine’s emerging research profile particularly interesting is that clinical trials have now documented meaningful benefits in conditions for which metformin has never been seriously studied. Two novel findings stand out.
Colorectal adenoma prevention
Colorectal polyps, called adenomas, are the precursors to colorectal cancer. Once removed during colonoscopy, they frequently recur. A multicenter, double-blind, randomized controlled trial published in 2020 by Chen, Gao, and colleagues enrolled 1,108 patients who had just undergone complete polypectomy across seven hospital centers in China. Participants received 0.3 g of berberine twice daily or a placebo for two years. Adenoma recurrence occurred in 36% of the berberine group versus 47% of the placebo group, a statistically significant relative risk reduction of 23%. The most common side effect was mild constipation in 1% of berberine participants. No serious adverse events were reported. [9]
This is a good result for taking berberine for two years, but there’s more. A six-year extended follow-up of those same patients by Tan, Zou, and colleagues at the same institution found that the protective effect of berberine persisted for at least six years after treatment had stopped. Adenoma recurrence was 34.7% in the berberine group versus 52.1% in the placebo group. The rate of any new colorectal neoplasm was also about 8% lower in those who had received berberine. This is not a surrogate biomarker finding. This is actual tumor prevention sustained years beyond the treatment period in a large multicenter trial. It seems to me that it would be best not to stop taking berberine if you’ve had adenomas removed and want to reduce the risk of adenoma recurrence or even colon cancer. [10]
Post-surgical atrial fibrillation
Atrial fibrillation after cardiac surgery is one of the most common and serious post-operative complications, occurring in roughly 30 to 40% of coronary artery bypass patients. A randomized, double-blind, placebo-controlled trial by Zhang and colleagues enrolled 200 bypass surgery patients. Those receiving berberine experienced postoperative atrial fibrillation in 20% of cases versus 35% in the placebo group, a hazard ratio of 0.50, meaning the risk was cut in half. Berberine also significantly reduced circulating CRP and interleukin-6, inflammatory markers elevated after surgery that drive arrhythmia risk. [11]
Better absorption at lower doses: Newer formulations
Berberine HCl has poor oral bioavailability. Less than 1% makes it into systemic circulation, which is why 1,500 milligrams a day are necessary to get results, and why all of that berberine sitting in the GI tract causes discomfort in many people. One emerging solution is to bind berberine to a phospholipid to form a berberine phytosome, which dramatically improves absorption across the gut wall.
A randomized, double-blind, placebo-controlled trial by Rondanelli and colleagues enrolled 49 overweight adults with impaired fasting glucose and tested berberine phytosome at 550 mg per tablet, twice daily. Each 550 mg tablet is standardized to 28–34% berberine, delivering about 180 mg of actual berberine per tablet, or 360 mg per day, a 75% reduction from the 1,500 mg daily dose used in older trials, yet with comparable clinical results. After 60 days, the supplemented group showed significant improvements in fasting glucose, total cholesterol, triglycerides, insulin, visceral adipose tissue, and fat mass compared to placebo, with no adverse events. [12]
A separate phytosome trial in women with PCOS using the same dose confirmed strong reproductive and metabolic benefits. Seventy percent of women in the berberine group resumed regular menstruation, compared with 16% in controls, and 60% had normalization of ovarian anatomy, compared with 13%. Acne and hirsutism also improved significantly, tolerability was excellent, and a number of women who had been trying for years to conceive became pregnant. [13] The phytosome formulation produces roughly 9 to 10 times greater plasma exposure than an equivalent dose of standard berberine, which explains how a 75% lower berberine dose achieves equivalent or better results.
Another promising form is dihydroberberine, the reduced uncharged form of berberine, which crosses the gut wall more efficiently and converts back to berberine inside cells. A 2021 crossover trial found that 100 mg of dihydroberberine achieved significantly higher plasma berberine concentrations than 500 mg of standard berberine. [14] Larger efficacy trials are still needed, but the absorption advantage is well-established in early data.
How strong is the evidence? An honest assessment
A comprehensive analysis using Consensus, an AI-powered scientific research platform searching over 170 million papers, including PubMed, found 43 studies directly addressing whether berberine is effective for metabolic syndrome and lipid profiles in humans. Fifty-six percent answered clearly yes, supported by large, high-quality RCTs and meta-analyses. Forty-two percent answered “possibly,” flagging methodological limitations including small sample sizes, short intervention periods, and primarily Chinese study populations. Zero percent concluded that berberine does not work.
The methodological limitations that led to 42% issuing a “possible” verdict are not a reason to dismiss berberine. The existing trials are real, peer-reviewed, and published in respected journals. The evidence all points in the same direction, even if some of the trials are small. What is missing is the kind of large, long-term, multi-site trial that only happens with a lot of financial incentive to fund it. Berberine is just a plant compound that can’t be patented. There’s not a lot of money to be made from selling berberine, so there’s no financial incentive to run those trials. That’s a reflection of market economics, not of the science.
What the evidence does support, clearly and consistently, is that berberine is a serious supplement with a genuine and growing clinical record. The effects on blood sugar, lipids, and inflammation are real. The colorectal adenoma data are remarkable. The post-surgical atrial fibrillation finding is striking. The safety profile across hundreds of trials is reassuring, with side effects typically limited to mild gastrointestinal symptoms and no evidence of liver or kidney toxicity at standard doses.
Berberine as a metabolic longevity tool
Berberine and metformin are generally thought of as tools to help with malfunctioning metabolism. But these tools could also be leveraged as longevity tools. Personally, that’s more my interest in berberine. I’m not going to take a drug to live longer, but I would consider using berberine, available without a prescription.
The longevity research community likes metformin as an anti-aging drug. It activates AMPK, has caloric restriction mimetic properties, and observational data suggest diabetics on metformin live longer than matched non-diabetic populations not taking the drug. The TAME trial (Targeting Aging with Metformin), led by Dr. Nir Barzilai, is currently enrolling 3,000 people aged 65 to 79 to formally test this.
Well, why not berberine? Berberine activates the same AMPK and mTOR pathways that sit at the center of virtually every serious longevity intervention, from caloric restriction and intermittent fasting to rapamycin. Animal studies have shown lifespan extension in C. elegans, Drosophila, and mice through antioxidant network activation, reduced cellular senescence, and improved mitochondrial function. No completed human longevity trial exists for berberine yet, and it would be overstating the case to claim otherwise.
What berberine does have is an impressive set of surrogate biomarkers. Chronically elevated blood glucose accelerates the formation of advanced glycation end-products, cross-linked proteins and fats that stiffen arteries, cloud lenses, and damage kidneys and nerves over decades. Lower glucose and A1c slow that process, even at levels within the “normal” range. Better lipid profiles reduce cardiovascular risk. Lower CRP and inflammatory cytokine levels reduce chronic inflammation that drives most age-related diseases. Berberine moves all of these in the right direction, consistently, across a wide range of populations. You don’t have to be diabetic to benefit from berberine. For anyone who wants to keep their metabolic biology running well into later life, that is a compelling argument.
Practical guidance: Who should consider berberine and how
Standard berberine hydrochloride is typically dosed at 500 mg three times daily with meals. Berberine phytosome is effective at approximately 360 mg of actual berberine per day (delivered as two 550 mg phytosome tablets), a much lower true berberine dose with better tolerability. Dihydroberberine is typically used at 100 to 200 milligrams twice daily. If you have tried standard berberine and struggled with digestive side effects, the phytosome formulation or dihydroberberine is worth discussing with your healthcare provider.
Berberine is most relevant for:
People with prediabetes or type 2 diabetes
Women with PCOS
People with metabolic syndrome
People who have had colorectal polyps removed
Health-conscious adults who want to optimize metabolism for longevity
There are a few safety notes. Berberine can meaningfully lower blood glucose, so anyone taking glucose-lowering medications, including metformin, sulfonylureas, or insulin, should monitor for hypoglycemia with their provider. Berberine also interacts with some medications processed by cytochrome P450 liver enzymes, so a medication review before starting is worthwhile. Avoid during pregnancy, as it has not been thoroughly tested in this state. Since quality varies significantly across manufacturers, sourcing from a reputable, third-party tested product matters.
As with all metabolic interventions, berberine is a tool, not a cure. For people with type 2 diabetes, the most powerful intervention available remains the lifestyle changes that reduce fat in the liver and pancreas below the personal fat threshold that triggers metabolic dysfunction. You can use berberine while you work on those lifestyle changes, and it may be valuable as a long-term supplement. The foundation is a diet rich in fruits and vegetables, along with adequate protein, staying active throughout the day, including resistance exercise, reducing stress, and getting good sleep.
If you are working to reverse type 2 diabetes and want personalized guidance on lifestyle, nutrition, and evidence-based supplements like berberine, visit EndDiabetesNow.co to learn more about 1:1 coaching with Dr. Michael Donaldson.
Read more from Michael Donaldson
Michael Donaldson, Nutrition Researcher & Health Coach
Dr. Michael Donaldson, Ph.D., is a leading voice in plant-based nutrition and lifestyle transformation. With a doctorate from Cornell University and more than two decades of research at Hallelujah Diet, he has helped thousands understand how food can restore health and vitality. Through his coaching platform End Diabetes Now, he guides clients in reversing type 2 diabetes naturally and sustainably. A scientist, entrepreneur, and educator, Dr. Donaldson also founded True Wealth Health Products and formulated Ora-Shield, an organic oral-care blend. His work bridges science, faith, and practical wisdom to help people achieve lasting wellness and purpose.
References:
[1] Yin, J., Xing, H., & Ye, J. (2008). Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: Clinical and Experimental, 57(5), 712–717.
[2] Zhang, Y., Gu, Y., Ren, H., et al. (2020). Gut microbiome-related effects of berberine and probiotics on type 2 diabetes (the PREMOTE study). Nature Communications, 11(1), 5015.
[3] Panigrahi, A., & Mohanty, S. (2023). Efficacy and safety of HIMABERB® Berberine on glycemic control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC Endocrine Disorders, 23(1), 190.
[4] Ji, L., Ma, J., Ma, Y., et al. (2025). Berberine ursodeoxycholate for the treatment of type 2 diabetes: a randomized clinical trial. JAMA Network Open, 8(3), e2462185.
[5] Wang, J., Bi, C., Xi, H., & Wei, F. (2024). Effects of administering berberine alone or in combination on type 2 diabetes mellitus: a systematic review and meta-analysis. Frontiers in Pharmacology, 15, 1455534.
[6] Zhao, J. V., Yeung, W.-F., Chan, Y.-H., et al. (2021). Effect of berberine on cardiovascular disease risk factors: a mechanistic randomized controlled trial. Nutrients, 13(8), 2550.
[7] Lei, L., Wang, B., Zhao, L., et al. (2026). Berberine and adiposity in diabetes-free individuals with obesity and MASLD: a randomized clinical trial. JAMA Network Open, 9(1), e2554152.
[8] Panigrahi, N., Verma, R., & Jadaun, P. (2022). Study on the effect of berberine, myoinositol, and metformin in women with polycystic ovary syndrome: a prospective randomised study. Cureus, 14, e21781.
[9] Chen, Y.-X., Gao, Q.-Y., Zou, T.-H., et al. (2020). Berberine versus placebo for the prevention of recurrence of colorectal adenoma: a multicentre, double-blinded, randomised controlled study. Lancet Gastroenterology & Hepatology, 5(3), 267–275.
[10] Tan, Y.-J., Zou, T.-H., Yu, K., et al. (2025). Berberine for preventing colorectal adenoma recurrence and neoplasm occurrence: 6-year follow-up of a randomized clinical trial. Cell Reports Medicine, 6(9), 102293.
[11] Zhang, J., Wang, Y., Jiang, H., et al. (2022). Preventive effect of berberine on postoperative atrial fibrillation. Circulation: Arrhythmia and Electrophysiology, 15(10), e011160.
[12] Rondanelli, M., Gasparri, C., Petrangolini, G., et al. (2023). Berberine phospholipid exerts a positive effect on the glycemic profile of overweight subjects with impaired fasting blood glucose (IFG): a randomized double-blind placebo-controlled clinical trial. European Review for Medical and Pharmacological Sciences, 27(14), 6718–6727.
[13] Di Pierro, F., Sultana, R., Eusaph, A. Z., et al. (2023). Effect of berberine phytosome on reproductive, dermatologic, and metabolic characteristics in women with polycystic ovary syndrome: a controlled, randomized, multi-centric, open-label clinical trial (NCT05480670). Frontiers in Pharmacology, 14, 1269605.
[14] Moon, J. M., Ratliff, K. M., Hagele, A. M., et al. (2021). Absorption kinetics of berberine and dihydroberberine and their impact on glycemia: a randomized, controlled, crossover pilot trial. Nutrients, 14(1), 124.
